CTBO (Cantabio Pharmaceuticals) Market Cap: $0.02 Mil (As of Jun. 26, 2026)


What is Cantabio Pharmaceuticals Market Cap?

Cantabio Pharmaceuticals CTBO Market Cap is $0.02 Mil as of Jun. 26, 2026.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Cantabio Pharmaceuticals's share price for the quarter that ended in Dec. 2018 was $42.5. Cantabio Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Dec. 2018 was 0.02 Mil. Therefore, Cantabio Pharmaceuticals's market cap for the quarter that ended in Dec. 2018 was $0.81 Mil.

Cantabio Pharmaceuticals's quarterly market cap declined from Jun. 2018 ($2.37 Mil) to Sep. 2018 ($1.38 Mil) and declined from Sep. 2018 ($1.38 Mil) to Dec. 2018 ($0.81 Mil).

Cantabio Pharmaceuticals's annual market cap declined from Mar. 2016 ($50.00 Mil) to Mar. 2017 ($3.88 Mil) and declined from Mar. 2017 ($3.88 Mil) to Mar. 2018 ($3.25 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Cantabio Pharmaceuticals's Enterprise Value for Today is $0.02 Mil.

Cantabio Pharmaceuticals  (OTCPK:CTBO) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Cantabio Pharmaceuticals Market Cap Related Terms

Cantabio Pharmaceuticals Market Cap Historical Data

* Premium members only.

The historical data trend for Cantabio Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantabio Pharmaceuticals Market Cap Chart

Cantabio Pharmaceuticals Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
Market Cap
Get a 7-Day Free Trial 0.00 0.00 50.00 3.88 3.25

Cantabio Pharmaceuticals Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.78 3.25 2.37 1.38 0.81

CTBO vs TNTY, ETNI, NTRR: Market Cap Comparison

For the Biotechnology subindustry, Cantabio Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cantabio Pharmaceuticals Market Cap vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cantabio Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Cantabio Pharmaceuticals's Market Cap falls into.


Cantabio Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Cantabio Pharmaceuticals's Market Cap for the fiscal year that ended in Mar. 2018 is calculated as

Market Cap (A: Mar. 2018 )=Share Price (A: Mar. 2018 )*Shares Outstanding (EOP) (A: Mar. 2018 )
=$324.5*0.010
=$3.25

Cantabio Pharmaceuticals's Market Cap for the quarter that ended in Dec. 2018 is calculated as

Market Cap (Q: Dec. 2018 )=Share Price (Q: Dec. 2018 )*Shares Outstanding (EOP) (Q: Dec. 2018 )
=$42.5*0.019
=$0.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of $0.02 Mil mean?
Cantabio Pharmaceuticals (CTBO) has a Market Cap of $0.02 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Cantabio Pharmaceuticals and its competitors.
Is Cantabio Pharmaceuticals' Market Cap too high?
Cantabio Pharmaceuticals' current Market Cap is $0.02 Mil. The Biotechnology industry median Market Cap is 113.83. Cantabio Pharmaceuticals' value of $0.02 Mil is 100% below this industry median.
How does Cantabio Pharmaceuticals' Market Cap compare to TNTY and ETNI?
Cantabio Pharmaceuticals' Market Cap of $0.02 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 113.83. Cantabio Pharmaceuticals' value of $0.02 Mil is 100% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cantabio Pharmaceuticals's current Market Cap of $0.02 Mil is 100% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Cantabio Pharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cantabio Pharmaceuticals's current Market Cap is $0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantabio Pharmaceuticals stock overvalued right now?
Cantabio Pharmaceuticals (CTBO) has a current Market Cap of $0.02 Mil. The current Market Cap is $0.02 Mil and 100% below the Biotechnology industry median of 113.83. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Cantabio Pharmaceuticals (CTBO), the current Market Cap is $0.02 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantabio Pharmaceuticals Business Description

Address 1250 Oakmead Parkway, Sunnyvale, CA, USA, 94085
Cantabio Pharmaceuticals Inc is the United States based preclinical stage biotechnology company. It is focused on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson's disease and Alzheimer's disease and other related diseases. In addition, In addition, it is also engaged in the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins which display loss of function during disease conditions.